Georgia Bio

The 2017 SEBIO’s Deal of the Year Award Winners Announced

11/20/2017

PINEHURST, NC – The winners of Southeast BIO’s (SEBIO) Deal of the Year awards were announced in a ceremony held at its 19th Annual Investor Forum in Pinehurst, North Carolina on November 15, 2017. Companies competed in the following categories: IPO VC Transaction Initial Funding Strategic Transaction Strategic Investment SEBIO Leadership Award

BIO Applauds Sens. Tillis and Peters for Introducing the Fostering Innovation Act

11/20/2017

The Fostering Innovation Act would build on the success of the JOBS Act and further reduce regulatory costs for biotech small businesses. Washington, DC (November 15, 2017) – Today, the Biotechnology Innovation Organization (BIO) applauds Sens. Thom Tillis (R-NC) and Gary Peters (D-MI) for introducing the Fostering Innovation Act. This vital legislation would build on the success of the JOBS Act and further reduce regulatory costs for biotech small businesses.

Aviragen, Vaxart merge to develop oral vaccines for influenza, norovirus and RSV

10/31/2017

For some antigens like norovirus and RSV, there are no approved vaccines. For others, like the seasonal flu, immunization rates are often far from ideal. Now, a new company, the product of a merger between Aviragen Therapeutics and Vaxart, aims to develop oral vaccines against these diseases. After the transaction, which executives believe will close early next year, the combined company will take Vaxart’s name. Vaxart CEO Walter Latour will lead the combined company and shares will trade on Nasdaq under the proposed ticker “VXRT.” The new Vaxart will have about $30 million in cash, which it will use to advance several key candidates in the company’s pipeline, Wouter Latour, M.D., CEO of Vaxart, said during a conference call on Monday about the transaction. Recent positive clinical data have derisked Vaxart’s platform, Aviragen CEO Joseph Patti, Ph.D., said on the call, leading the Nasdaq-listed company to pursue the merger after an extensive review of about 60 strategic options.

Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment

10/25/2017

Lexington, MA – October 25, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, today announced the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation to Shire’s gene therapy candidate SHP654 (also designated as BAX 888), an investigational factor VIII (FVIII) gene therapy for the treatment of hemophilia A. The regulatory agency also granted Shire investigational new drug (IND) status for SHP654.

Biden Cancer Initiative President & FasterCures Executive Director to Keynote Georgia Bio Innovation Summit October 24

10/20/2017

Atlanta, GA (October 20, 2017) – The Georgia Bio Innovation Summit will welcome patient advocate and visionary strategist Greg Simon, who leads the Biden Cancer Initiative, and Kim McCleary, Acting Executive Director at FasterCures, a center of the Milken Institute, as the plenary speakers for the October 24, 2017 event at Cobb Galleria.

The future of drug pricing: Value over volume

10/19/2017

Doctors and hospitals are increasingly being paid not for the quantity of care they provide, but for the outcome or quality of care patients receive. The emerging trend in health care is about rewarding value, rather than volume. This is the future, where there is less focus on the number of tests or treatments a patient receives and more focus on whether a patient’s health is improving.

Intent Solutions™ Well Positioned to Address U.S. Opioid Crisis

10/17/2017

ATLANTA (Oct. 17, 2017) — Intent Solutions™, creator of the breakthrough medical device technology, TAD™, has rounded out its executive team in preparation for going commercial later this year, which puts the company in a promising position to address the ongoing national opioid crisis. The commercialization efforts follow the company’s successful $1.5 million seed round capital raise in 2016 and an additional $1.5M in 2017.

Atlanta biomedical company @CryoLife buying German company for $225M

10/11/2017

CryoLife has entered into a definitive agreement to acquire JOTEC AG (“JOTEC”). JOTEC is a German-based, privately-held developer of technologically differentiated endovascular stent grafts, and cardiac and vascular surgical grafts, focused on aortic repair. The combination of CryoLife and JOTEC will create a Company with a broad and highly competitive product portfolio focused on aortic surgery, and will position CryoLife to compete strongly in the important and growing endovascular surgical markets.

Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg

10/05/2017

PDUFA Date Set For May 26, 2018 MALVERN, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA date of May 26, 2018 for its decision on the New Drug Application (NDA) for for intravenous (IV) meloxicam 30mg for the management of moderate to severe pain.

Emory University research funding breaks new record, $628M for FY 2017

09/26/2017

Emory University reported Monday that it pocketed $628 million in external research funding in fiscal year 2017, an increase from $574.6 million the year before and a new record high. Emory attributed the big increase to "groundbreaking results and the promise of future discoveries with the potential to change the face of science and medicine." Researchers in Emory's Woodruff Health Sciences Center (WHSC) received more than $584.8 million in FY17, or more than 93 percent of the university total. The WHSC includes schools of medicine, public health, nursing, Yerkes National Primate Research Center, Winship Cancer Institute and Emory Healthcare. Of the 2017 total, more than 61 percent, or $384 million, came from federal agencies.

News Posts List